Related Experiment Videos
[Isolated persistent thrombocytopenia after autologous bone marrow grafting]
A S Carret1, Y Loriette, M J Bezou
1Service de pédiatrie B, Hôtel-Dieu, Clermont-Ferrand, France.
Pediatrie
|January 1, 1990
Summary
A boy treated for acute promyelocytic leukemia developed persistent thrombocytopenic purpura after bone marrow transplants. This condition was linked to autoimmune factors and antiplatelet antibodies.
Area of Science:
- Hematology
- Oncology
- Immunology
Background:
- Acute promyelocytic leukemia (APL) is a subtype of leukemia.
- Treatment protocols like LAME 86 involve chemotherapy agents such as aracytin and rubidomycin.
- Autologous bone marrow transplantation is a consolidation therapy for leukemia.
Observation:
- A patient with APL developed persistent thrombocytopenic purpura post-transplantation.
- This purpura manifested as a decrease in platelet survival time.
- Elevated levels of antiplatelet antibodies were detected.
Findings:
- The persistent thrombocytopenic purpura following autologous bone marrow transplantation in an APL patient was determined to be of autoimmune origin.
- The presence of high levels of antiplatelet antibodies confirmed the autoimmune etiology.
- Reduced platelet survival time further supported the autoimmune diagnosis.
Implications:
- This case highlights a potential complication of autologous bone marrow transplantation in APL patients.
- It underscores the importance of monitoring for and diagnosing autoimmune phenomena post-transplant.
- Understanding the autoimmune basis is crucial for managing such complications and informing future treatment strategies.